Category: Article
-
Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference
October 23, 2024 Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical trials. The conference will include…
-
Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
September, 2023 Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to…
-
Andarix Pharmaceuticals to Lead Panel Discussion at Clinical Trial Conference
July 11, 2023 Conference Highlights Key Features of Successful Clinical Trial Management SOMERVILLE, MA — July 11, 2023 — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will lead a panel discussion composed of industry experts on the key components of clinical trial management…
-
Andarix Pharmaceuticals to Participate in Life Science Panel of Biotech and MedTech Entrepreneurs at Life Science Summit 22
November 2, 2022 Personalized and targeted medicine for lung and other cancers SOMERVILLE, MA —November 2, 2022— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will participate on a panel discussion of biotech company formation and management experiences. The panel will be part of…
-
Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office.
-
Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address the ability of theranostic technology to provide personalized medicine to diagnose and treat breast cancer. The three main types…
-
Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference
Targeted therapy for breast cancer is based on personalized medicine approach SOMERVILLE, MA — April 24, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address…
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study…
-
Andarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the CBI Basket and Umbrella Trials for Oncology Conference in Philadelphia, Pennsylvania on Oct 17-18, 2018.
-
Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto, Japan.